拜瑞妥一个疗程多久？

(Rivaroxaban) is a new type of oral anticoagulant that has a safe, effective, simple and intuitive anticoagulant effect. Xarelto, as a new type of oral anticoagulant, can selectively and directly inhibit coagulation factor Xa without the assistance of antithrombin cofactors, inhibiting the generation of thrombin and the formation of thrombus. This is also where Xarelto is different from the anticoagulation mechanism of traditional anticoagulants (such as low molecular weight heparin). It has good compliance and is more convenient to use. Today we will learn more about how long a course of Xarelto treatment lasts?

The treatment courses for Xarelto (rivaroxaban) are different for different indications:

1. Xarelto prevents venous thrombosis in adult patients undergoing elective hip or knee replacement surgery, as follows:

The recommended dose is 10 mg of Xarelto taken orally once daily. If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery.

For patients undergoing major hip surgery, the recommended course of treatment is 35 days.

For patients undergoing major knee surgery, the recommended course of treatment is 12 days.

If a missed dose occurs, patients should take Xarelto immediately and continue taking the dose once daily the next day.

2. Xarelto (rivaroxaban) treats DVT (venous thrombosis) and reduces the risk of acute DVT recurrence and PE, as follows:

The recommended dose for initial treatment of acute DVT is 15 mg twice daily for the first three weeks, followed by 20 mg once daily for maintenance treatment and to reduce the risk of recurrent DVT and PE.

3. Xarelto is used in adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism, as follows:

The recommended dose of Xarelto (rivaroxaban) is 20 mg once a day, which is also the maximum recommended dose. For patients with low body weight and elderly patients (>75 years old), doctors can use 15 mg once a day as appropriate based on the patient's condition.

A domestic study compared 32 patients each in the Xarelto group and the warfarin group. The results showed that the total effective rate of treatment in the Xarelto group was 96.88%, which was higher than the warfarin group. The incidence of adverse reactions in the Xarelto (rivaroxaban) group was 3.13%, which was lower than the warfarin group. These results show that Xarelto has similar efficacy to standard treatment, but with fewer major bleeding events and less intracranial bleeding in critical areas than the standard treatment group.

  The above is the content of the (rivaroxaban) treatment course, I hope it can help you!

Recommended related hot articles: /newsDetail/76640.html